Refine
Year of publication
Document Type
- Doctoral Thesis (96) (remove)
Has Fulltext
- yes (96)
Is part of the Bibliography
- no (96)
Keywords
- Heterologe Genexpression (3)
- Endothelin (2)
- G-Protein gekoppelte Rezeptoren (2)
- Gentherapie (2)
- HIV (2)
- Membrane Proteins (2)
- NMR-Spektroskopie (2)
- gene therapy (2)
- 5-Lipoxygenase (1)
- APOBEC3G (1)
Institute
- Biochemie und Chemie (63)
- Biochemie, Chemie und Pharmazie (29)
- Pharmazie (5)
- Biowissenschaften (1)
- Georg-Speyer-Haus (1)
Solute carrier (SLC) are related to various diseases in human and promising pharmaceutical targets but more structural and functional information on SLCs is required to expand their use for drug design and therapy. The 7-transmembrane segment inverted (7-TMIR) fold was identified for the SLC families 4, 23 and 26 in the last decade thus detailed analysis of the structure function relationship of one of these families might also yield insights for the other two. SVCT1 and SVCT2 from the SLC23 family are sodium dependent ascorbic acid transporters in human but structural analysis of the SLC23 family is exclusively based on two homologs – UraA from E. coli and UapA from A. nidulans – yielding two inward-facing and one occluded conformation. In combination with outward-facing conformations from SLC4 transporters, and additional information from the SLC26 family, an elevator transport mechanism for all 7-TMIR proteins was identified but detailed mechanistic features of the transport remain elusive due to the lack of multiple conformations from individual transporters.
To increase the understanding of 7-TMIR protein structure and function in this study, the transport mechanism of SLC23 transporters was analyzed by two strategies including selection of alpaca derived nanobodies and synthetic nanobodies against UraA as prokaryotic model protein of the SLC23 family. The second strategy involved mutagenesis of UraA at functional relevant positions regarding the conformational change during transport. Therefore, available structures of 7-TMIR proteins and less related elevator transporters were analyzed and a common motif identified – the alpha helical inter-domain linkers. The proposed rigid body movement for transport in combination with the characteristic alpha helical secondary structure of the linkers connecting both rigid bodies led to the hypothesis of functional relevance of the linkers and a conformational hinge being located in close proximity to the linkers. These positions were identified and used to modulate the biophysical properties of the transporter. Mutagenesis at three relevant positions led to loss of transport functionality and these UraA variants could be recombinantly produced and purified to further examine the underlying mechanistic effects. The variants UraAG320P and UraAP330G from the periplasmic inter-domain linker showed increased dimerization and thermal stability as well as substrate binding in solution. The substrate affinity of UraAG320P was identified to be 5-fold higher compared to the wildtype. The solvent accessibility of the substrate binding site in UraAG320P and UraAP330G revealed reduced open probability that indicated an altered conformational space compared to UraAWT. This phenomenon was analyzed in more detail by differential hydrogen-deuterium exchange mass spectrometry and the results supported the hypothesis of a reduced open probability and gave further insights into the impact of the two mutations in the periplasmic inter-domain linker in UraA.
This thesis further presents strategies for phage display selection of nanobodies with epitope bias and a post selection analysis pipeline to identify nanobodies with desired binding characteristics. Thereby, whole cell transport inhibition highlighted periplasmic epitope binders and conformational selectivity. A cytoplasmic epitope could be identified by pulldown with inside-out membrane vesicles for one cytoplasmic side binder. Thermal stabilization analysis of the target protein in differential scanning fluorometry was performed in presence of two different nanobodies to identify simultaneous binding by additional thermal stabilization respectively competition by intermediate melting temperatures. Combination of epitope information with simultaneous DSF could be used to identify the stabilization of different UraA conformations by a set of binders and presents a general nanobody selection strategy for other SLCs. Synthetic nanobodies (sybodies) were also included in the analysis pipeline and Sy45 identified as promising candidate for co-crystallization that gave rise to UraAWT crystals in several conditions in presence or absence of uracil. Similar crystals could be obtained in combination with UraAG320P that were further optimized to gain structural information on this mutant. The structure was solved by molecular replacement and the model refined at 3.1 Å resolution confirming the cytoplasmic epitope of Sy45 as predicted by the selection pipeline. The stabilized conformation was inward-facing similar to the reported UapA structure but significantly different to the previously reported inward-facing structure of UraA. The structure further confirmed the structural integrity of the UraA mutant G320P. Despite the monomeric state of UraA in the structure, the gate domain aligned reasonably well with the gate domain of the previously published dimeric UraA structure in the occluded conformation and allowed detailed analysis of the conformational transition in UraA from inward-facing to occluded by a single rigid body movement. Thereby little movement in the gate domain of UraA was observed in contrast to a previously reported transport mechanism. Core domain rotation around a rotation axis parallel to the substrate barrier was found to explain the major part of conformational transition from inward-facing to occluded and experimentally supported the hypothesized mechanism by Chang et al. (2017). Additionally, the conformational hinge around position G320 in UraA could be identified as well as the impact of the backbone rigidity introduced by the highly conserved proline residue at position 330 in UraA on the conformational transition. This position was found to serve as anchoring point the inter-domain linker and determines the coordinated movement of inter-domain linker and core domain. The functional analysis further highlighted the requirement of alpha helical secondary structure within the inter-domain linker that serves as amphipathic structural entity that can adjust to changed core-gate domain distances and angles during transport by extension/compression or bending while preserving the rigid linkage.
The applied strategies to modulate the conformational space of UraA by mutagenesis at the hinge positions in the inter-domain linkers is transferrable to other transporters and might facilitate their structural and functional characterization.
Further, this study discusses the conformational thermostabilization of UraA that is based on increased melting temperatures upon restriction of its conformational freedom. The term ‘conformational thermostabilization’ introduced by Serrano-Vega et al. (2007) could be experimentally supported and the direct correlation between the conformational freedom and thermostabilization was qualitatively analyzed for UraA. The concept of conformational thermostabilization might help in characterization of other dynamic transport systems as well.
Ubiquitination is regarded as one of the key post-translational modifications in nearly all biological processes, endowed with numerous layers of complexity. Deubiquitinating enzymes (DUBs) dynamically counterbalance ubiquitination events by deconjugating ubiquitin signals from substrates. Dysregulation of the ubiquitin code and its negative regulators drive various pathologies, such as neurological disorders and cancer.
The DUB ubiquitin-specific peptidase 22 (USP22) is well-known for its essential role in the human Spt-Ada-Gcn5 acetyltransferase (SAGA) complex, mediating the removal of monoubiquitination events from Histone 2A and 2B (H2A and -B), thereby regulating gene transcription. In cancer, USP22 was initially described as a part of an 11-gene expression signature profile, predicting tumor metastasis, reoccurrence and death after therapy in a wide range of tumor cells. However, novel roles for USP22 have emerged recently, accrediting USP22 essential roles in regulating tumor development as well as apoptotic cell death signaling.
One of the hallmarks of cancer is the evasion of cell death, especially apoptosis, a form of programmed cell death (PCD). Necroptosis, a regulated form of necrosis, is regarded as an attractive therapeutic strategy to overcome apoptosis-resistance in tumor cells, although a profound understanding of the exact signaling cascade still remains elusive. Nevertheless, several ubiquitination and deubiquitination events are described in fine-tuning necroptotic signaling.
In this study, we describe a novel role for USP22 in regulating necroptotic cell death signaling in human tumor cell lines. USP22 depletion significantly delayed TNFa/Smac mimetic/zVAD.fmk (TBZ)-induced necroptosis, without affecting TNFa-induced nuclear factor-kappa B (NF-KB) signaling or TNFa-mediated extrinsic apoptosis. Intriguingly, re-expression of USP22 wildtype in the USP22 knockout background could re-sensitize HT-29 cells to TBZ-induced necroptosis, whereas re-constitution with the catalytic inactive mutant USP22 Cys185Ser did not rescue susceptibility to TBZ-induced necroptosis, confirming the USP22 DUB-function a pivotal role in regulating necroptotic cell death. USP22 depletion facilitated ubiquitination and unexpectedly also phosphorylation of Receptor-interacting protein kinase 3 (RIPK3) during necroptosis induction, as shown by Tandem Ubiquitin Binding Entities (TUBE) pulldowns and in vivo (de)ubiquitination immunoprecipitations. To substantiate our findings, we performed mass-spectrometric ubiquitin remnant profiling and identified the three novel USP22-regulated RIPK3 ubiquitination sites Lysine (K) 42, K351 and K518 upon TBZ-induced necroptosis. Further assessment of these ubiquitination sites unraveled, that mutation of K518 in RIPK3 reduced necroptosis-associated RIPK3 ubiquitination and additionally affected RIPK3 phosphorylation upon necroptosis induction. At the same time, genetic knock-in of RIPK3 K518R sensitizes tumor cells to TNFa-induced necroptotic cell death and amplified necrosome formation.
In summary we identified USP22 as a new regulator of TBZ-induced necroptosis in various human tumor cell lines and further unraveled the distinctive role of DUBs and (de)ubiquitination events in controlling programmed cell death signaling.
Einige Teilergebnisse dieser Arbeit wurden bereits veröffentlicht: Mahnke K., Schönfeld K., Fondel S. et al (2007), Int. J. Cancer 120; 2723-2733 Depletion of CD4+CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro Im ersten Teil dieser Arbeit wurde die Treg depletierende Wirkung von ONTAK, einem Fusionsprotein aus Interleukin-2 und Diphterietoxin, untersucht. Hierzu wurde ONTAK in Zellkultur auf humanen Lymphozyten getestet und anschließend Melanomapatienten verabreicht. ONTAK konnte sowohl in vitro als auch in vivo eine Depletion von Tregs induzieren, wenngleich der in vivo Effekt nicht vollständig war. Des Weiteren wurde der immunologische Effekt, der auf die Reduktion der Tregs zurückzuführen ist, untersucht. Hierzu wurden die Patienten mit DCP behandelt, welches normalerweise zu einer schwachen Entzündungsreaktion führt. Nach Treg Depletion wurden starke Kontaktekzeme in den Patienten induziert. Aufgrund dieser verstärkten Immunantwort erfolgte eine Applikation der Tumorpeptide MART1 und gp100 in das Kontaktekzem. Anschließend konnten peptidspezifische CD8 T-Zell Populationen detektiert werden, die sowohl INF-γ sekretierten, als auch zytotoxisch aktiv waren. Solche starken Immunantworten wurden bisher nur unter zu Hilfenahme starker Adjuvanzien induziert. ONATK führt bereits nach einmaliger Applikation zu einer Depletion regulatorischer T-Zellen in vivo. Dabei wird der Gehalt von 4 % regulatorischen T-Zellen im Blut auf einen Gehalt von 1 % gesenkt. Diese Depletion der Tregs verstärkt eine Immunisierung mit Peptiden, die eine starke CD8 T-Zell vermittelte Immunantwort induziert. Allerdings kam es zu keiner vollständigen Depletion der Tregs, was durch die geringe in vivo Halbwertszeit von ONTAK, sowie durch unbekannte Mechanismen der Treg Homöostase erklärt werden könnte. Die Wirkweise von ONTAK konnte nur im Blut, aber nicht in anderen Organen wie z.B. Lymphknoten erforscht werden, daher besteht die Möglichkeit, einer unvollständigen Depletion der Zellen in peripheren Organen. In wieweit Tregs im Blut mit anderen Zellen wechselwirken ist weitgehenst unerforscht. Die meisten Untersuchungen zeigen Zell-Zell Interaktionen in den Lymphknoten und im entzündeten Gewebe. Der Ort, an dem die Tregs aber wirklich ihr suppressives Potential auf andere Zellen entfalten, ist noch unbekannt. Hiermit beschäftigt sich der zweite Teil dieser Arbeit. Zur Beantwortung dieser Frage sollten Tregs in vivo in Mäusen in die Haut oder den Lymphknoten geleitet werden. Um das Vorhaben auszuführen, wurden die Zytokinrezeptoren CCR7, CCR9 und CCR10 sowie die Adhäsionsmoleküle PSGL-1, ESL-1 und CD103 kloniert und in zwei Expressionssystemen getestet. Ein lentivirales System zeigte eine schlechte Transduktionseffizienz, so dass ein zweites System mit einer Elektroporationstechnik, der Nucleofection gewählt wurde. Dieses führte zu Expressionseffizienzen von ca. 40 %. Zuerst wurde die Funktionalität der klonierten Moleküle in vitro in der murinen T-Zellline EL-4 in Transwell- und Flowchamberversuchen demonstriert, anschließend wurden murine in vitro expandierte Tregs nucleofiziert. Eine umfassende Analyse der nucleofizierten Zellen zeigte eine Heraufregulation von CD69 und eine Herunteregulation von CD62L, was auf eine Aktivierung der Zellen deutet. Mit einhergehender Aktivierung nahm auch die Apoptoserate der Zellen zu, diese konnte auch durch Modifikationen der Nucleofections- sowie der Kulturbedingungen nicht verringert werden. Nach einer Inkubationszeit von 16 Stunden nach der Nucleofection ließen sich noch adhäsive Eigenschaften der exprimierten Moleküle in der Flowchamber nachweisen. Im Suppressionstest, in dem die Zellen über einen Zeitraum von drei Tagen inkubiert wurden, waren die Zellen jedoch nicht mehr suppressiv. Daher wären die in vivo Versuche, die den suppressiven Einfluß der Tregs auf die Ohrschwellung in Abhängigkeit ihrer Lokalisation untersuchen sollten, erfolglos geblieben. Mit der Induktion der Apoptose stießen die hier verwendeten Methoden an ihre Grenzen. Zur Realisierung des Projekts müssten andere Transduktionssysteme oder Tregs aus knock out Mäusen verwendet werden. Regulatorische T-Zellen nehmen eine Schlüsselrolle bei der Suppression von anti-Tumor Immunantworten aber auch bei dem Schutz vor Autoimmunerkrankungen ein. Eine erfolgreiche Manipulation dieser Zellen in vivo oder in vitro bildet eine solide Basis für neuartige Immuntherapien gegen entsprechende Krankheiten. ONTAK ist ein wirkungsvolles Medikament, um die Anzahl der regulatorischen Zellen in vvo zu reduzieren. Es trägt dadurch zu einer verstärkten Immunantwort bei. Eine einmalige Gabe von ONTAK ist sicherlich nicht ausreichend, um Tumore zu bekämpfen, es kann aber Immuntherapien unterstützen. Eine Manipulation von Tregs, durch die Expression von Transgenen um ihr Migrationsverhalten in vivo zu beeinflussen und damit die Suppression von Autoimmunerkrankungen zu bedingen, ist noch nicht ausgereift und bedarf noch weiterer Forschung.
Post-translational modifications (PTMs) of cell fate regulating proteins determine their stability, localization and function and control the activation of cell protective signaling pathways. Particularly in aberrantly dividing cancer cells the surveillance of cell cycle progression is essential to control tumorigenicity. In a variety of carcinomas, lymphomas and leukemias, the tumor-suppressive functions of the apoptosis- and senescence-regulating promyelocytic leukemia protein (PML) is controlled by numerous PTMs. PML poly-ubiquitylation and polySUMOylation at several lysine (K) residues induce PML degradation that is correlated to a progressive and invasive cancer phenotype. Besides several known E3 ubiquitin protein ligases that are involved in PML degradation, less is known about PML-specific deubiquitylases (DUBs), the respective DUB-controlled ubiquitin conjugation sites and the functional consequences of PML (de)ubiquitylation. Here, we show that the pro-tumorigenic DUB USP22 critically regulates PML protein stability by modifying PML residue K394 in advanced colon carcinoma cells in vitro and that this modification also impacts the homeostasis and function of the leukemia-associated mutant variant PML-RARα. We found that ablation of USP22 decreases PML mono-ubiquitylation and correlates with a prolonged protein half-live in colon carcinoma and acute promyelocytic leukemia (APL) cell lines. Additionally, silencing of USP22 enhances interferon and interferon-stimulated gene (ISG) expression in APL cells in vitro, which together with prolonged PML-RARα stability increases the APL cell sensitivity towards differentiation treatment. In accordance with the novel roles of USP22 as suppressor of the interferon response in human intestinal epithelial cells (hIECs), our findings imply USP22-dependent surveillance of PML-RARα stability and interferon signaling in human leukemia cells, revealing USP22 as central regulator of leukemia pathogenesis.
Autophagy, together with the ubiquitin-proteasome system, is the main quality control pathway responsible for maintaining cell homeostasis. There are several types of autophagy distinguished by cargo selectivity and means of induction. This thesis focuses on macroautophagy, hereafter autophagy, where a double-layered membrane is formed originating from the endoplasmatic reticulum (ER) engulfing cargo selectively or unselectively. Subsequently, a vesicle forms around the cargo, an autophagosome, and eventually fuses with the lysosome leading to degradation of the vesicle content and release of the cargo “building blocks”. Basal autophagy continuously occurs, unselectively engulfing a portion of the cytoplasm. However, autophagy can also be induced by stress such as starvation, protein aggregation, damaged organelles, intracellular pathogens etc. In this case, the cargo is selectively targeted, and the fate of the autophagosome is the same as in basal autophagy. In recent years, interest in identifying mechanisms of autophagy regulation has risen due to its importance in neurodegenerative diseases and cancer. Given the complexity of the process, its execution is tightly regulated from initiation, autophagosome formation, expansion, closure, and finally fusion with the lysosome. Each of the steps involves different protein complexes, whose timely activity is orchestrated by post-translational modifications. One of them is ubiquitination. Ubiquitin is a small, 76-amino acid protein conjugated in a 3-step reaction to other proteins, in a reversible manner, meaning undone by deubiquitinases. Originally described as a degradation signal targeting proteins to the proteasome, today it is known it has various additional non-proteolytic functions, such as regulating a protein’s activity, localization, or interaction partners. The role of ubiquitin in autophagy has already been shown. However, given the reversibility and fine-tuning of the ubiquitin signal, many expected regulators remain unidentified. This work aimed to identify novel deubiquitinating enzymes that regulate autophagy. We identified ubiquitin-specific protease 11 (USP11) as a novel, negative regulator of autophagy. Loss of USP11 leads to an increase in autophagic flux, whereas overexpression of USP11 attenuates it. Moreover, this observation was reproducible in model organism Caenorhabditis elegans, emphasizing the importance of USP11 in autophagy regulation. To identify the mechanism of USP11-dependent autophagy regulation, we performed a USP11 interactome screen after 4 hour Torin1 treatment and identified a plethora of autophagy-related proteins. Following the most prominent hits, we have investigated versatile ways in which USP11 regulates autophagy. USP11 interacts with the PI3KC3 complex, the role of which is phosphorylating lipids of the ER, thereby initiating the formation of the autophagosomal membrane. Phosphorylated lipids serve as a recruitment signal for downstream effector proteins necessary for the membrane expansion. The core components of the complex are VPS34, the lipid kinase, ATG14, the protein responsible for targeting the complex to the ER, VPS15, a pseudokinase with a scaffolding role, Beclin1, a regulatory subunit, and NRBF2, the dimer-inducing subunit. We have found USP11 interacts with the complex and, based on its activity, USP11 influences post-translational status of all the aforementioned subunits, except for ATG14. Moreover, we have found that loss of USP11 leads to an increase in NRBF2 levels, whereas it does not change the levels of the other proteins. Given that the dimerization of the complex leads to an increase in complex activity, we investigated if the complex is more tightly formed in the absence of USP11, and if it is more active. We have found both to be the case. Although the exact mechanism of USP11-dependent PI3KC3 complex regulation remains to be identified, we found that loss of USP11 stimulates the complex formation and activity, likely contributing to the general effect of USP11 on autophagy flux. Additionally, we found that USP11 modulates levels of mTOR, the most upstream kinase in autophagy initiation steps and general multifaceted metabolism regulator. Loss of USP11 led to downregulation of mTOR levels, suggesting USP11 may rescue mTOR from proteasome-mediated degradation. Furthermore, we found mTOR to be differentially modified depending on the activity of USP11. However, it remains to be shown if USP11-dependent mTOR regulation contributes to the observed autophagy phenotype. Taken together, USP11 is a novel, versatile, negative regulator of autophagy, and an important addition to our knowledge on the regulation of autophagy by the ubiquitin system.
Im Rahmen dieser Arbeit sollte untersucht werden, ob eine Zellzyklusabhängigkeit der CD95- vermittelten Apoptose besteht. Dazu wurde ein ecdysoninduzierbares Genexpressionsystem für die induzierte Überexpression der CDK-Inhibitoren p21 und p27 in RKO-Zellen (Kolonkarzinomzellen) zur Herbeiführung eines Zellzyklusarrests in der G1-Phase benutzt. Nach Induktion mit dem Ecdysonhomolog Muristeron wurde durch Zugabe von rekombinanten hCD95-Liganden Apoptose ausgelöst und anschließend untersucht. Die erzielten Ergebnisse zeigen, dass der Induktor Muristeron an sich und nicht die p21- bzw. p27-Überexpression die anti-apoptotische Akt-Kinase aktiviert, die Expression des anti-apoptotischen Bcl-xL erhöht, die Caspase-8-Aktivierung (entweder am CD95-DISC oder durch "Feedback"-Aktivierung durch Caspase-3) und die darauf folgenden Ereignisse verhindert und somit die hCD95L-induzierte Apoptose blockiert. Zusätzlich beeinflusst der Induktor auch das Genexpressionsmuster der behandelten Zellen, was ebenfalls für die Hemmung der Apoptose mit verantwortlich sein könnte. Somit ist das ecdysoninduzierbare Genexpressionsystem zur Apoptoseuntersuchung in RKO-Zellen nicht verwendbar. Mit der Untersuchung des Apoptoseverhaltens proliferierender RKO-Zellen konnte gezeigt werden, dass überlebende Zellen nach hCD95L-Behandlung vermehrt in der G0/G1-Zellzyklusphase nachweisbar sind, während apoptotische (Caspase-3-positive) Zellen aus der G2/M-Phase heraus sterben. Allerdings weisen die apoptotischen Zellen kaum Cyclin B1 auf, ein für die G2-Phase wichtiges und typisches Cyclin. Somit bleibt die genaue Verknüpfung von Zellzyklusregulation und Apoptose auch nach diesen Analysen ungeklärt. In einem dritten Ansatz - Zellzyklusarrest durch Dichtearretierung - konnte eine Hemmung der CD95- vermittelten Apoptose in der arretierten Zellpopulation nachgewiesen werden. Allerdings sekretieren RKO-Zellen einen anti-apoptotischen Faktor in ihr Medium, dessen Konzentration und Wirkung mit größerer Zelldichte zunimmt und somit für die Protektion, unabhängig von Zellzyklusarrest oder Proliferation, verantwortlich ist. Konfluente und auch mit konditioniertem Medium behandelte RKO-Zellen zeigen im Vergleich zu dünn ausgesäten RKO-Zellen Veränderungen, die denen sehr ähnlich sind die beim Übergang einer epithelverankerten Zelle zu einer migrierenden Einzelzelle (EMT) auftreten. Beispielsweise verändert sich die Zusammensetzung des Zytoskeletts, die Zellen verlieren den Zell-Zell-Kontakt und lösen sich ab, bleiben aber am Leben. Zusätzlich steigt die Sekretion von Zytokinen an, die Angiogenese, Migration und Invasion positiv beeinflussen. Sowohl konfluente als auch mit konditioniertem Medium behandelte sub-konfluente Zellen sind apoptoseresistent (hCD95L, TRAIL, UV, Staurosporin), woran u.a. die Kinasen PKC und PI3K, aber auch das anti-apoptotische Bcl-xL beteiligt sind. Die Zellen sterben interessanterweise, wenn ein agonistischer anti-CD95-Antikörper statt des rekombinanten CD95-Liganden verwendet wird, was vermuten lässt, dass eine mangelhafte Vernetzung der einzelnen DISC-Komplexe zur Apoptosehemmung führt, welche durch den Antikörper dann aber erzwungen wird. Zwar handelt es sich hierbei um ein reines Zellkulturmodell, dennoch könnte es bedeuten, dass die Umgebung in einer dichten RKO-Zellkultur vergleichbar ist mit der in größeren soliden Tumoren. Die Zellen brauchen Nährstoffe, versuchen über eine Neovaskularisierung Anschluss an ein Blutsystem zu finden und sekretieren Lockstoffe, Wachstumsfaktoren sowie Proteasen, um die Metastasierung zu erleichtern. PI3K, cPKCs und Bcl-xL tragen dabei zu einer Apoptoseresistenz bei, welche die Zellen zum einen resistent gegenüber Anoikis, Nährstoffmangel, aber auch gegen angreifende zytotoxische T-Zellen macht. Eine weitere Aufklärung der hier ablaufenden Prozesse würde es erleichtern, Möglichkeiten zu finden, in diese Signalwege einzugreifen, um die Apoptosesensitivität wieder herzustellen und die Metastasierung zu verhindern. Insbesondere ist die Identifizierung des für die Apoptoseprotektion verantwortlichen Zytokins das nächste wichtige Ziel bei der Fortsetzung dieser Arbeiten.